Paper Details

  1. Home
  2. Paper Details

Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study.

Author: GalliLaura, MiserocchiElisabetta, ModoratiGiulio, RamaPaolo

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A one-year treatment with oral valacyclovir (500 mg daily) was as effective and well-tolerated as acyclovir (400 mg twice daily) in reducing the recurrence rate of ocular herpes simplex virus (HSV) disease. The recurrence rate was 23.1% in both groups, with no significant differences in the frequency or severity of side effects.
Paper Details　
Original Abstract of the Article :
PURPOSE: To compare the efficacy of one-year treatment with valacyclovir vs acyclovir in preventing recurrence of the herpes simplex virus (HSV) eye disease. DESIGN: Prospective, randomized, clinical trial pilot study. METHODS: Fifty-two immunocompetent patients with a history of recurrent ocular ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ajo.2007.06.001

データ提供：米国国立医学図書館（NLM）

Valacyclovir vs. Acyclovir: A Comparison for Recurrent Herpes Simplex Virus Eye Disease

This study explores the world of herpes simplex virus (HSV) eye disease, a condition that can cause discomfort and vision problems. Imagine a camel caravan traveling through a desert, and one of the camels becomes infected with a virus. This is similar to HSV eye disease, which can cause inflammation and infection in the eye. The researchers wanted to compare the effectiveness of two antiviral medications, valacyclovir and acyclovir, in preventing recurrent HSV eye disease.

Valacyclovir and Acyclovir: A Side-by-Side Comparison

The researchers conducted a randomized, controlled trial with patients who had a history of recurrent HSV eye disease. They found that both valacyclovir and acyclovir were equally effective in preventing recurrences, with no significant difference in side effects. This is like having two different types of camels that are both equally capable of navigating the desert, each with its own unique set of strengths and weaknesses.

Finding the Right Treatment for HSV Eye Disease

This research provides valuable information for patients with recurrent HSV eye disease. It demonstrates that both valacyclovir and acyclovir are effective options, and that the choice between the two may come down to individual factors such as cost, convenience, or personal preferences. This is like having a map that shows two different routes through the desert, allowing you to choose the one that best suits your needs and resources.

Dr.Camel's Conclusion

This study provides valuable insights into the treatment of recurrent HSV eye disease. It highlights the importance of finding the right treatment for individual needs, just like choosing the best camel to carry you through the desert. As we continue to explore the vast landscapes of ophthalmology, we are discovering new ways to combat viral infections and protect our vision.

Date :
  1. Date Completed 2007-10-29
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

17692271

DOI: Digital Object Identifier

10.1016/j.ajo.2007.06.001

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.